EA201290757A1 - Бициклические соединения и их применение в качестве ингибиторов двойного действия c-src/jak - Google Patents

Бициклические соединения и их применение в качестве ингибиторов двойного действия c-src/jak

Info

Publication number
EA201290757A1
EA201290757A1 EA201290757A EA201290757A EA201290757A1 EA 201290757 A1 EA201290757 A1 EA 201290757A1 EA 201290757 A EA201290757 A EA 201290757A EA 201290757 A EA201290757 A EA 201290757A EA 201290757 A1 EA201290757 A1 EA 201290757A1
Authority
EA
Eurasian Patent Office
Prior art keywords
src
compounds
inhibitors
application
bicyclic compounds
Prior art date
Application number
EA201290757A
Other languages
English (en)
Inventor
Андрес МакАллистер
Максимилиен Мурон
Саумитра Сенгупта
Шанкар Джаярам Шетти
Original Assignee
Дебиофарм С.А.
Ауриджен Дискавери Текнолоджис Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дебиофарм С.А., Ауриджен Дискавери Текнолоджис Лтд. filed Critical Дебиофарм С.А.
Publication of EA201290757A1 publication Critical patent/EA201290757A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к замещенным ароматическим бициклическим соединениям, содержащим пиримидиновые и пиридиновые кольца, а также к фармацевтически приемлемым солям указанных соединений. Соединения согласно изобретению подходят для применения в качестве ингибиторов тирозинкиназы, предпочтительно в качестве ингибиторов киназ семейства SRC (SFK's), в частности в качестве ингибиторов множественного действия SFK/JAK киназ, и даже предпочтительно в качестве ингибиторов двойного действия c-SRC/JAK киназ, что приводит к ингибированию активации STAT3 и, следовательно, аномального роста определенных типов клеток. Соединения согласно изобретению в особенности подходят для применения при лечении или ингибировании определенных заболеваний, являющихся результатом нарушений регуляции STAT3.
EA201290757A 2010-02-17 2011-02-17 Бициклические соединения и их применение в качестве ингибиторов двойного действия c-src/jak EA201290757A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN415CH2010 2010-02-17
PCT/IB2011/050669 WO2011101806A1 (en) 2010-02-17 2011-02-17 Bicyclic compounds and their uses as dual c-src / jak inhibitors

Publications (1)

Publication Number Publication Date
EA201290757A1 true EA201290757A1 (ru) 2013-04-30

Family

ID=43903941

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290757A EA201290757A1 (ru) 2010-02-17 2011-02-17 Бициклические соединения и их применение в качестве ингибиторов двойного действия c-src/jak

Country Status (28)

Country Link
US (2) US8440679B2 (ru)
EP (1) EP2536722B1 (ru)
JP (1) JP2013519725A (ru)
KR (1) KR20120130294A (ru)
CN (1) CN102858770A (ru)
AR (1) AR089641A1 (ru)
AU (1) AU2011216895B2 (ru)
BR (1) BR112012020639A2 (ru)
CA (1) CA2789655A1 (ru)
CU (1) CU20120118A7 (ru)
CY (1) CY1115420T1 (ru)
DK (1) DK2536722T3 (ru)
EA (1) EA201290757A1 (ru)
ES (1) ES2470190T3 (ru)
HK (1) HK1178897A1 (ru)
HR (1) HRP20140437T1 (ru)
IL (1) IL221487A (ru)
MX (1) MX2012009482A (ru)
NZ (1) NZ602271A (ru)
PL (1) PL2536722T3 (ru)
PT (1) PT2536722E (ru)
RS (1) RS53458B (ru)
SA (1) SA111320200B1 (ru)
SG (1) SG183329A1 (ru)
SI (1) SI2536722T1 (ru)
SM (1) SMT201400090B (ru)
TW (1) TW201130838A (ru)
WO (1) WO2011101806A1 (ru)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2611588T3 (es) 2005-12-13 2017-05-09 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
LT3070090T (lt) 2007-06-13 2019-06-25 Incyte Holdings Corporation Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
EA020494B1 (ru) 2009-05-22 2014-11-28 Инсайт Корпорейшн 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
NZ602313A (en) 2010-03-10 2014-08-29 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
ME02445B (me) 2010-05-21 2016-09-20 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9388176B2 (en) 2012-03-12 2016-07-12 Allergan, Inc. Method of treating conditiions with kinase inhibitors
WO2013138396A1 (en) 2012-03-12 2013-09-19 Allergan, Inc. Dihydropyridopyrimidine and dihydronaphthyridine derivatives as tyrosine kinase inhibitors of especially vegf and pdgf
CN107383009B (zh) 2012-06-13 2020-06-09 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
LT2919766T (lt) 2012-11-15 2021-09-27 Incyte Holdings Corporation Ruksolitinibo pailginto atpalaidavimo vaisto formos
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
SG10201707259PA (en) 2013-03-06 2017-10-30 Incyte Corp Processes and intermediates for making a jak inhibitor
CN105263931B (zh) 2013-04-19 2019-01-25 因赛特公司 作为fgfr抑制剂的双环杂环
WO2014196793A1 (en) * 2013-06-05 2014-12-11 C&C Research Laboratories Heterocyclic derivatives and use thereof
ES2792549T3 (es) 2013-08-07 2020-11-11 Incyte Corp Formas de dosificación de liberación sostenida para un inhibidor de JAK1
DK3572416T3 (da) 2014-01-24 2022-12-12 Turning Point Therapeutics Inc Diaryl-makrocykler som modulatorer af proteinkinaser
KR102456088B1 (ko) 2014-04-04 2022-10-19 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9321766B1 (en) 2014-10-06 2016-04-26 Allergan, Inc. Kinase inhibitors
US9296747B1 (en) 2014-10-10 2016-03-29 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
KR20180033194A (ko) 2015-07-21 2018-04-02 티피 테라퓨틱스, 인크. 키랄 디아릴 매크로사이클 및 이것의 용도
CN107459519A (zh) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288A (zh) 2017-02-28 2019-12-17 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3064837A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
WO2018222917A1 (en) * 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
AU2018306328B2 (en) 2017-07-28 2023-03-09 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR20200101358A (ko) 2017-12-19 2020-08-27 터닝 포인트 테라퓨틱스, 인크. 질병 치료용 대환식 화합물
BR112020014913A2 (pt) 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Métodos para uso de células t car
AR114810A1 (es) 2018-01-30 2020-10-21 Incyte Corp Procesos e intermedios para elaborar un inhibidor de jak
AU2019245420A1 (en) 2018-03-30 2020-11-12 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
JP2021523118A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の塩
CN109485643A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种芴酮类stat3抑制剂及制备方法与应用
CN109293641A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种芴类stat3抑制剂及其制备方法
CN109180657A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 Stat3抑制剂的制备方法
CN109336868A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 吲哚类stat3抑制剂及其制备方法
CN109369627A (zh) * 2018-10-31 2019-02-22 南京先进生物材料与过程装备研究院有限公司 芴酮类stat3抑制剂晶型a及制备方法
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4349472A (en) 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
DE69939168D1 (de) * 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6989385B2 (en) * 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA06003996A (es) * 2003-10-08 2006-07-05 Irm Llc Compuestos y composiciones como inhibidores de la proteina cinasa.
CN101374840B (zh) 2006-01-31 2011-09-28 霍夫曼-拉罗奇有限公司 7h-吡啶并[3,4-d]嘧啶-8-酮、它们的制备及作为蛋白激酶抑制剂的应用
WO2008077062A2 (en) 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
LT3070090T (lt) 2007-06-13 2019-06-25 Incyte Holdings Corporation Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
WO2009046448A1 (en) * 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8183245B2 (en) 2007-10-25 2012-05-22 Merck Sharp & Dohme Corp. Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة

Also Published As

Publication number Publication date
AU2011216895A1 (en) 2012-09-27
AR089641A1 (es) 2014-09-10
US20130143895A1 (en) 2013-06-06
CN102858770A (zh) 2013-01-02
US8962637B2 (en) 2015-02-24
US8440679B2 (en) 2013-05-14
BR112012020639A2 (pt) 2017-08-08
AU2011216895B2 (en) 2015-11-05
ES2470190T3 (es) 2014-06-23
CA2789655A1 (en) 2011-08-25
JP2013519725A (ja) 2013-05-30
DK2536722T3 (da) 2014-05-26
HRP20140437T1 (hr) 2014-08-29
EP2536722B1 (en) 2014-04-16
NZ602271A (en) 2013-09-27
PL2536722T3 (pl) 2014-11-28
HK1178897A1 (en) 2013-09-19
CY1115420T1 (el) 2017-01-04
WO2011101806A1 (en) 2011-08-25
CU20120118A7 (es) 2012-10-15
SA111320200B1 (ar) 2014-02-16
EP2536722A1 (en) 2012-12-26
KR20120130294A (ko) 2012-11-30
SG183329A1 (en) 2012-09-27
PT2536722E (pt) 2014-05-26
MX2012009482A (es) 2012-11-29
SI2536722T1 (sl) 2014-10-30
RS53458B (en) 2014-12-31
IL221487A (en) 2014-11-30
US20130012518A1 (en) 2013-01-10
TW201130838A (en) 2011-09-16
SMT201400090B (it) 2014-09-08

Similar Documents

Publication Publication Date Title
EA201290757A1 (ru) Бициклические соединения и их применение в качестве ингибиторов двойного действия c-src/jak
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
EA201491356A1 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
HK1135103A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX342329B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
EA201790267A1 (ru) Новые модуляторы киназ
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
EA201270339A1 (ru) Замещенные производные ксантина
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
EA201390520A1 (ru) Замещенные соединения пиридазинкарбоксамида